Cohance Lifesciences Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Endurance Technologies Ltd, Time Technoplast Ltd, Jyoti CNC Automation Ltd and Lemon Tree Hotels Ltd are among the other losers in the BSE's 'A' group today, 13 November 2025.

Cohance Lifesciences Ltd lost 8.38% to Rs 631.75 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.69 lakh shares were traded on the counter so far as against the average daily volumes of 67428 shares in the past one month.

Endurance Technologies Ltd tumbled 7.67% to Rs 2692.6. The stock was the second biggest loser in 'A' group.On the BSE, 15663 shares were traded on the counter so far as against the average daily volumes of 7578 shares in the past one month.

Time Technoplast Ltd crashed 6.14% to Rs 201. The stock was the third biggest loser in 'A' group.On the BSE, 2.33 lakh shares were traded on the counter so far as against the average daily volumes of 59774 shares in the past one month.

Jyoti CNC Automation Ltd fell 5.61% to Rs 933.5. The stock was the fourth biggest loser in 'A' group.On the BSE, 45463 shares were traded on the counter so far as against the average daily volumes of 78342 shares in the past one month.

Lemon Tree Hotels Ltd shed 4.85% to Rs 155.1. The stock was the fifth biggest loser in 'A' group.On the BSE, 1.9 lakh shares were traded on the counter so far as against the average daily volumes of 1.34 lakh shares in the past one month.

Powered by Capital Market - Live News

The decline in revenue was primarily due to deferred shipments at the company?s CDMO and FDF sites and some key molecule destocking, and timing of certain project starts, especially at NJ Bio. Adjusting for de-stocking the quarter reported growth of 14%YoY.

Profit before tax (PBT) dropped 51.9% YoY to Rs 83.77 crore in Q2 FY26

Adjusted EBITDA for the quarter was Rs 128.9 crore, with Adjusted EBITDA margins of 23.2%, reflecting the lower volumes, upfront investments in employee costs and certain transition and remediation costs.

On half-yearly basis, the company?s consolidated net profit tumbled 42.5% to Rs 122.96 crore despite of 1.2% increase in revenue from operations to Rs 1,104.88 crore in H1 FY26 over H1 FY25.

On the outlook front, the company stated that it remains on track to achieve its $ 1 billion (Rs 8,500 crore) revenue target by 2030, with mid-30s EBITDA margins. Investments in the team, business development and broadening of customer base over the last 12 months will help to achieve the targets.

Vivek Sharma, executive chairman, said: ?As we move from integration to capability amplification, Cohance is now firmly focused on building the science platforms, operational backbone, and governance needed to power our next phase of growth.

The revised organization structure strengthened leadership team, position us strongly on the path toward our US$1 billion vision. We?ve unveiled our new brand identity at CPHI Frankfurt, deepened our customer engagements across the U.S., Europe, and Japan, and continue to attract exceptional talent across our businesses.

While near-term challenges such as pharma destocking, biotech funding delays, and the temporary Nacharam plant shutdown have impacted reported growth, our fundamentals remain strong. We achieved a key regulatory milestone with a late-phase molecule approval in the U.S., added new biotech partnerships, and successfully completed multiple customer audits. Demand from large innovators remains healthy, and we see clear tailwinds as global customers increasingly seek to diversify supply chains and partner with technology-led CDMOs like Cohance.?

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals.

Powered by Capital Market - Live News

Net profit of Cohance Lifesciences declined 46.50% to Rs 74.08 crore in the quarter ended September 2025 as against Rs 138.47 crore during the previous quarter ended September 2024. Sales declined 7.98% to Rs 555.57 crore in the quarter ended September 2025 as against Rs 603.77 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

However, he will continue to be available with the company in terms of his contractual terms with the company and to facilitate seamless transition of his duties and responsibilities.

Further, the board of Cohance Lifesciences has approved the appointment of Himanshu Agarwal, presently designated as chief financial officer, as an additional director of the company, for a period of five years with effect from 29 October 2025.

The appointment of Himanshu Agarwal will be subject to approval of the shareholders of the company.

Himanshu Agarwal has been associated with the company as CFO from January 2, 2024. He started his professional career in 1991 and in his over 30 years of work experience has worked across multiple countries, locations and finance profiles and has gathered a wide and diversified view of business and finance.

Before Joining Cohance, he has worked with MNC?s like ICI India, Huhtamaki oyj, and earlier CFO and whole-time director of AkzoNobel India and as the CFO of Astra Zeneca Pharma, Bennett, Coleman & Co.

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals.

On consolidated basis, the company's net profit (adjusted) stood at Rs 62.9 crore in Q1 FY26, down 24.8% year-on-year from Rs 83.5 crore in Q1 FY25. Revenue from operations rose 12.5% YoY to Rs 549.3 crore in Q1 FY26 from Rs 488.1 crore in Q1 FY25.

The scrip had tumbled 7.98% to end at Rs 786.35 on the BSE today.

Powered by Capital Market - Live News